Uploaded September 2025 | Updated September 2026, 2 weeks ago
Drug development costs continue to escalate as innovators struggle with lengthy approval timelines that can run a decade or more. With FDA user fee negotiations approaching and the Trump Administration increasing pressure to reduce prices, policy reforms leveraging artificial intelligence and real-world evidence could bring down costs and get valuable new treatments and cures safely and quickly to patients.
Join Former FDA Commissioner Scott Gottlieb, Former FDA Acting Commissioner Janet Woodcock, ArsenalBio CEO Ken Drazan and other experts on Friday, September 19, for a discussion that will explore pathways for sustainable FDA reform and pharmaceutical innovation. Lowell Schiller, Nonresident Senior Scholar and former FDA Acting Chief Counsel, will also present on a new Schaeffer Center white paper outlining policy recommendations to advance medical product innovation and patient access.
Drug development costs continue to escalate as innovators struggle with lengthy approval timelines that can run a decade or more. With FDA user fee negotiations approaching and the Trump Administration increasing pressure to reduce prices, policy reforms leveraging artificial intelligence and real-world evidence could bring down costs and get valuable new treatments and cures safely and quickly to patients.
Join Former FDA Commissioner Scott Gottlieb, Former FDA Acting Commissioner Janet Woodcock, ArsenalBio CEO Ken Drazan and other experts on Friday, September 19, for a discussion that will explore pathways for sustainable FDA reform and pharmaceutical innovation. Lowell Schiller, Nonresident Senior Scholar and former FDA Acting Chief Counsel, will also present on a new Schaeffer Center white paper outlining policy recommendations to advance medical product innovation and patient access.
